Zentalis Pharmaceuticals ZNTL 深 沪
等待开盘 10-17 09:30:00 美东时间
2.13
-0.110
-4.91%
华盛通- 最 高2.30
- 今 开2.25
- 成交量 110.18万股
- 最 低 2.10
- 昨 收 2.24
- 总市值 2.02亿
- 52周最高 6.95
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 1.212
- 委 比 -19.40%
- 总股本 9467.19万
- 历史最高 87.19
- 量 比 1.19
- 振 幅 8.93%
- 历史最低 1.01
- 每 手 1
- 风险率 1.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zentalis Pharmaceuticals收跌4.91%，成交额237.72万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
今天 06:44
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8
Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.
10-05 21:00
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted 62,000 non-qualified stock options to three new employees on October 1, 2026, under the 2022 Inducement Plan. The options, exercisable at $2.605 per share, vest over four years with 25% after one year and the remaining 75% in monthly installments over the next three years. The company focuses on developing a first-in-class WEE1 inhibitor for ovarian cancer treatment.
10-01 21:10
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.
09-16 23:08
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted 269,000 non-qualified stock options to four new employees under its 2022 Inducement Plan. The options, exercisable at $3.71 per share, vest over four years and require continued employment. Zentalis, focused on developing a WEE1 inhibitor for ovarian cancer, aims to provide targeted, non-chemo treatments to improve patient outcomes.
09-01 21:15
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform ...
08-20 16:53
Stocks to watch on Thursday after hours: AMAT, DLO, ZNTL
Wall Street's benchmark S&P 500 pushed up to yet another all-time trading high on Thursday as investors digested July producer price data that showed wholesale inflation was unchanged from the previou...
08-14 04:28
Zentalis Pharmaceuticals shares are trading lower after the company announced a proposed public offering.
Zentalis Pharmaceuticals shares are trading lower after the company announced a proposed public offering.
08-14 04:25
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
<p>Zentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and pre-funded warrants. The company plans to use the net proceeds, along with existing cash, to fund clinical trials, regulatory filings, manufacturing, and other corporate purposes. The offering is subject to market conditions, and the underwriters have a 30-day option to purchase additional shares. The offering is bei...
08-13 20:01
